Moles After Accutane (Isotretinoin): What Changes and What's Normal

Isotretinoin is a retinoid — a derivative of vitamin A — that dramatically reduces sebaceous gland activity. The on-treatment effects extend beyond acne control:

Thinning of the outermost skin layer, making skin more fragile.

Decreased oil production across the entire skin surface.

Increased UV sensitivity, with higher rates of sunburn at lower exposure.

Changes in melanocyte behaviour, less well-characterised but real.

Most of these effects reverse over months after stopping treatment. Some — particularly photosensitivity and certain pigmentation patterns — can persist longer or permanently in a minority of users.

Reported changes during isotretinoin courses (typically 4-9 months):

New pigmented spots, often light brown, on sun-exposed areas. These are usually post-inflammatory hyperpigmentation from healed acne lesions plus the photosensitive skin response, not new moles in the developmental sense.

Darkening of existing moles in some users, usually mild and uniform.

Melasma-like patches on the face, particularly in users with darker skin types.

Persistent redness or pink tone in healed acne sites.

Lightening (rather than darkening) of some pigmented marks in some users.

What is not consistently reported: rapid emergence of single concerning lesions specifically tied to isotretinoin. Most pigmentation effects are diffuse (across many spots) rather than focal (one specific lesion changing dramatically).

The most common pattern in user reports is 'I have many new moles since starting Accutane.' Three things explain most of these reports:

First, photosensitive skin during isotretinoin combined with normal sun exposure produces more lentigines (sun spots) than the same exposure would in untreated skin. These look like flat light brown moles. They are essentially benign hyperpigmentation responses, not melanoma.

Second, isotretinoin courses often coincide with periods of careful skin attention. Users who have spent months looking at acne now have a hyper-noticing baseline. Pre-existing small moles get noticed for the first time. The moles are not new; the noticing is.

Third, some genuinely new moles do form. Adults form new moles at low background rates regardless of medication, and the formation appears mildly elevated during isotretinoin in some studies. Most of these are benign.

What is not strongly supported: a meaningful increase in melanoma risk from isotretinoin. Studies looking at long-term skin cancer outcomes in isotretinoin users have not consistently shown elevated melanoma rates. The medication is not a melanoma carcinogen at standard therapeutic doses.

These are the changes worth dermatology attention regardless of whether you are on isotretinoin:

A single mole that has changed clearly and selectively, while other moles have not.

A new mole that is asymmetric, has irregular borders, or shows multiple colours.

A new pigmented spot over 6mm at first appearance.

A non-healing sore, ulcer, or scab that has not closed in 4 weeks.

A pigmented streak under a fingernail or toenail.

A raised firm bump that has been growing over weeks.

Notice that none of these is specific to isotretinoin. The medication does not change which features are concerning — it just adds background diffuse pigmentation that can make focal changes harder to spot. The ugly-duckling check (looking for the mole that's different from the rest) becomes especially valuable in this context.

Photosensitivity is one of the strongest documented effects of isotretinoin. Skin burns more easily and at lower UV doses. The practical consequence is that sun protection during isotretinoin matters more than at baseline.

During treatment: SPF 50 broad-spectrum sunscreen daily on exposed areas. Hat and UPF clothing in high UV. Reapply every 2 hours of outdoor exposure. Avoid intentional tanning entirely (this should already be off the menu given general skin cancer risk, but isotretinoin makes it acutely worse).

After treatment: photosensitivity resolves over months to a year. Sun protection habits should remain — the pigmentation marks accumulated during the photosensitive period are largely permanent and predict future skin cancer risk in those areas.

The long-term skin cancer significance of isotretinoin courses is less about the medication itself and more about the higher UV damage that accumulated during the photosensitive period if sun protection was incomplete.

Continue monthly self-exams as usual. Two adjustments help.

First, photograph baseline before starting if possible. If you are already on the medication, photograph as early as you can. The diffuse pigmentation changes during treatment are easier to interpret against a baseline.

Second, focus on the ugly-duckling check rather than feature-counting. With many moles potentially changing mildly and uniformly, the most useful signal is the mole that's different from the rest. Selective change in one lesion is the strongest signal.

A dermatology visit at the start of treatment (often arranged through the prescribing dermatologist) and at 6-12 months after the course ends gives you bookend professional checks. Between those, monthly self-exam is sufficient unless you find something that meets the warning criteria above.

Some pigmentation effects persist after isotretinoin courses end. Post-inflammatory marks from healed acne can remain for 6-18 months or longer. Lentigines from sun damage during the photosensitive period are essentially permanent. Melasma may persist or fade slowly.

These are cosmetic concerns, not skin cancer concerns. Treatment options for persistent post-isotretinoin pigmentation include topical retinoids (lower-dose adapalene or tretinoin), hydroquinone short courses, chemical peels, and laser treatments. None of these is necessary medically; they are aesthetic choices.

The distinction that matters: pigmentation marks that have been stable for 6+ months are not concerning regardless of how dark or persistent they are. Pigmentation that continues to evolve, has irregular features, or develops into raised lesions is concerning regardless of the original cause.